Education
About Us
Working with TipRanks
Follow Us
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (HK:8329)
:8329
RESEARCH TOOLSreports
8329 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.12 - HK$0.38
Previous CloseN/A
Volume90.00K
Average Volume (3M)513.33K
Market Cap
HK$295.33M
Enterprise ValueHK$108.80M
Total Cash (Recent Filing)HK$283.42M
Total Debt (Recent Filing)¥105.43M
Price to Earnings (P/E)10.9
Beta0.15
Next Earnings
Aug 08, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 15, 2025Dividend Yield3.05%
Share Statistics
EPS (TTM)0.02
Shares Outstanding426,000,000
10 Day Avg. Volume653,000
30 Day Avg. Volume513,333
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.12 and its highest was HK$0.38 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$295.33M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 08, 2025 which is in 34 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.005 which represents an annual dividend yield of 3.05%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.78%
12-Months-Change
Fundamentals
Return on Equity
2.72%
Trailing 12-Months
Asset Growth
-4.54%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) is a biotechnology company based in Shenzhen, China, primarily focused on the research, development, manufacturing, and distribution of biopharmaceutical products. The company operates within the healthcare and pharmaceutical sectors and offers a range of products including vaccines, therapeutic biological products, and diagnostic reagents. With a strong emphasis on innovation, Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. aims to contribute to public health by providing high-quality medical solutions.
Technical Analysis
Huakang Biomedical Holdings Company Limited
―
Fusen Pharmaceutical Co., Ltd.
―
China NT Pharma Group Co., Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―